Clinical Trials Logo

Abdominal Compartment Syndrome clinical trials

View clinical trials related to Abdominal Compartment Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04585555 Completed - Acute Kidney Injury Clinical Trials

Physiologic Signals and Signatures With the Accuryn Monitoring System (The Accuryn Registry)

Start date: July 10, 2017
Phase:
Study type: Observational [Patient Registry]

The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System.

NCT ID: NCT02514135 Completed - Clinical trials for Intra-Abdominal Hypertension

Intra-abdominal Hypertension in Critically Ill Patients

Start date: September 1, 2015
Phase:
Study type: Observational

The aim of the proposed study is to determine the incidence and prevalence of intra-abdominal hypertension and abdominal compartment syndrome in consecutive intensive care admissions using broad inclusion criteria.

NCT ID: NCT02319213 Completed - Clinical trials for Abdominal Compartment Syndrome

This Study Performed to Develop a New Technique for Measuring the Intra Abdominal Pressure

Start date: March 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the changes of intraocular pressure due to the increase of intra abdominal pressure.

NCT ID: NCT01553422 Completed - Clinical trials for Abdominal Compartment Syndrome

Relation Between Intrabdominal Pressure and Collapsibility Index of Inferior Vena Cava Before and After Fluid Therapy

Start date: March 2012
Phase: Phase 4
Study type: Interventional

This study assess the relation between intra abdominal pressure and collapsibility index of inferior vena cava in emergency bedside ultrasonography before and after fluid therapy.

NCT ID: NCT01355094 Completed - Clinical trials for Intra-abdominal Hypertension

Peritoneal Vacuum Therapy to Reduce Inflammatory Response From Abdominal Sepsis/Injury

SAD
Start date: June 2011
Phase: N/A
Study type: Interventional

This pilot study will evaluate the effectiveness in actively removing the peritoneal fluid through the use of a commercial suction device compared to passive drainage of the same peritoneal fluid drained through standard surgical drains under bulb suction only, in critically ill patients who require an "open abdomen". Both techniques being used, the commercial KCI AbTheraâ„¢ device and home made "Stampede" VAC system, are currently approved for use in Canada and used in our facility. The use or non-use of the open abdomen and its relationship to intra-abdominal hypertension (IAH) and the abdominal compartment syndrome (ACS), the level of IAH must be treated and if so how should be treated - remain controversial. The ultimate treatment for IAH/ACS is to leave the abdominal fascia open after laparotomy, utilizing some form of temporary abdominal closure (TAC) techniques, resulting in an "open abdomen"(OA). The decision to accept an OA can only be made in the operating room and is typically made quite arbitrarily (there is no current standard or protocol),and the TAC used is based on the surgeon's best judgment. The study intends to randomize patients after it has been decided that a TAC is required, which will be applied in the operating room while the patient is fully anesthetized. The only intervention required is to obtain small aliquots (a teaspoonful-15ml) of blood for the evaluation of inflammatory mediators levels, as well as the same volume of intra-peritoneal fluid-that is typically discarded in patients with OA.

NCT ID: NCT00890383 Completed - Clinical trials for Abdominal Compartment Syndrome

Colloids in Severe Trauma

CIST
Start date: May 2009
Phase: Phase 4
Study type: Interventional

Background: Fluid resuscitation is a cornerstone of the initial management of the critically injured trauma patient yet there are numerous controversies surrounding this very common practice. As a result, these controversies have been the subject of numerous clinical trials, evidence-based guidelines and systematic reviews. With the publication of the landmark SAFE Study the equipoise between the 2 treatments (which were representative solutions for colloid and crystalloids respectively), 4% albumin and saline, was established. This has however been brought into further doubt by the paucity of data on the use of hydroxyethylstarches (HES), which are less costly and have less side effects than albumin, in trauma. More recent findings by Gruen and colleagues have shown that as much as 5% of all trauma deaths are the result of fluid overload based on the North American fluid management model for trauma (pure crystalloid fluid management). A meta-analysis done by Kern and Shoemaker found that supranormal fluid resuscitation with crystalloids is beneficial when given before the onset of organ failure in critically ill surgical patients. Balogh and colleagues found out that when supranormal fuid resuscitation with crystalloids was applied to victims of severe trauma, this resulted in a statistically significant increase in the incidence of mortality, multiple organ failure, intra-abdominal hypertension (IAH) and abdominal compartment syndrome (ACS). More recently, Kirkpatrick and colleagues reviewed and defined a 'secondary' ACS as a direct result of fluid resuscitation. They concluded that "excess resuscitation with crystalloid fluids might be harming patients and contributing to an increased occurrence of ACS." This study will serve as a pilot to test the hypothesis that there will be significant differences in clinical outcomes for patients with severe trauma treated with colloid (HES) plus crystalloid and crystalloid only fluid management regimens, most notably the incidence of IAH and ACS. It is hoped that the hybrid colloid (HES) plus crystalloid fluid management regimen will provide a means to avoid the untoward fluid overload and/or other complications of pure crystalloid fluid management and the costs/complications of albumin administration.